Dirk Arnold, Andres Cervantes, Michel Pierre Ducreux, Sae-Won Han, Heinz-Josef Lenz, Kei Muro, Kanwal Pratap Singh Raghav, Lin Shen, Chao-Yuan Wang, Pei Jye Voon, Hung-Chih Hsu, Bing Xia, Ryota Iwasawa, Shamita Carrigan, Brooke Diorio, Patricia A. Lorenzini, Sandip Acharya, Seema Niphadkar Sethi, Mahadi Baig, Filippo Pietrantonio. "OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided
            <i>RAS</i>
            /
            <i>BRAF</i>
            wild-type metastatic colorectal cancer.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.tps3636